These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 17175118)

  • 1. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
    Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. (Int j radiat oncol biol phys 2007;67:651-659).
    Messerschmidt GL; Oleka N
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651-2; author reply 1652. PubMed ID: 18035221
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
    Rudat V; Münter M; Rades D; Grötz KA; Bajrovic A; Haberkorn U; Brenner W; Debus J
    Radiother Oncol; 2008 Oct; 89(1):71-80. PubMed ID: 18707782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In regards to Münter et Al. (Int J Radiat Oncol Biol Phys 2007;67:651-659).
    Samuels MA
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):318; author reply 318-9. PubMed ID: 17707287
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scintigraphy in prediction of the salivary gland function after gland-sparing intensity modulated radiation therapy for head and neck cancer.
    Tenhunen M; Collan J; Kouri M; Kangasmäki A; Heikkonen J; Kairemo K; Mäkitie A; Joensuu H; Saarilahti K
    Radiother Oncol; 2008 May; 87(2):260-7. PubMed ID: 18329118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life.
    Chen WC; Lai CH; Lee TF; Hung CH; Liu KC; Tsai MF; Wang WH; Chen H; Fang FM; Chen MF
    Oral Oncol; 2013 Jan; 49(1):42-8. PubMed ID: 22854066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective investigation and literature review of tolerance dose on salivary glands using quantitative salivary gland scintigraphy in the intensity-modulated radiotherapy era.
    Lee SW; Kang KW; Wu HG
    Head Neck; 2016 Apr; 38 Suppl 1():E1746-55. PubMed ID: 26875880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer.
    Bussels B; Maes A; Flamen P; Lambin P; Erven K; Hermans R; Nuyts S; Weltens C; Cecere S; Lesaffre E; Van den Bogaert W
    Radiother Oncol; 2004 Dec; 73(3):297-306. PubMed ID: 15588874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumours.
    Liem IH; Olmos RA; Balm AJ; Keus RB; van Tinteren H; Takes RP; Muller SH; Bruce AM; Hoefnagel CA; Hilgers FJ
    Eur J Nucl Med; 1996 Nov; 23(11):1485-90. PubMed ID: 8854847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
    Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E
    J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective longitudinal assessment of parotid gland function using dynamic quantitative pertechnate scintigraphy and estimation of dose-response relationship of parotid-sparing radiotherapy in head-neck cancers.
    Gupta T; Hotwani C; Kannan S; Master Z; Rangarajan V; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal JP
    Radiat Oncol; 2015 Mar; 10():67. PubMed ID: 25889705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
    Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of salivary flow and dose-volume modeling of complication incidence in patients with head-and-neck cancer receiving intensity-modulated radiotherapy.
    Marzi S; Iaccarino G; Pasciuti K; Soriani A; Benassi M; Arcangeli G; Giovinazzo G; Benassi M; Marucci L
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1252-9. PubMed ID: 19251097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Quantitative and qualitative investigations of salivary gland function in dependence on irradiation dose and volume for reduction of xerostomia in patients with head-and-neck cancer].
    Kuhnt T; Jirsak N; Müller AC; Pelz T; Gernhardt C; Schaller HG; Janich M; Gerlach R; Dunst J
    Strahlenther Onkol; 2005 Aug; 181(8):520-8. PubMed ID: 16044220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy requirements for head and neck intensity-modulated radiation therapy based on observed dose response of the major salivary glands.
    Kapanen M; Collan J; Saarilahti K; Heikkonen J; Kairemo K; Tenhunen M
    Radiother Oncol; 2009 Oct; 93(1):109-14. PubMed ID: 19435641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigations on parotid gland recovery after IMRT in head and neck tumor patients.
    Stock M; Dörr W; Stromberger C; Mock U; Koizar S; Pötter R; Georg D
    Strahlenther Onkol; 2010 Dec; 186(12):665-71. PubMed ID: 21136030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.